Other notable innovations involve the use of photoactive nanoparticles for restoring vision (US20200113843A1) [101], the delivery of IL-33 via adeno-associated virus (AAV) vector gene therapy for managing AMD (WO2022074370A1) [102], and pharmaceutical formulations with inorganic nanoparticles selected from titanium oxide or silica nanoparticles as an active ingredient for angiogenesis-related conditions, including age-related macular degeneration (US20140044753A1) [103]. The gene discussed is IL33; the disease is age-related macular degeneration.